Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 516

1.

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaeybroeck B, Klaasen R, van Onna M, Bernelot Moens HJ, Visser H, Schilder AM, Kok MR, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

BMC Rheumatol. 2019 Jun 13;3:3. doi: 10.1186/s41927-019-0071-x. eCollection 2019. Erratum in: BMC Rheumatol. 2019 Aug 20;3:35.

2.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

3.

Patient Self-Management and Tracking: A European Experience.

van Riel PLCM, Zuidema RM, Vogel C, Rongen-van Dartel SAA.

Rheum Dis Clin North Am. 2019 May;45(2):187-195. doi: 10.1016/j.rdc.2019.01.008. Review.

4.

The Development and Evaluation of Personalized Training in Shared Decision-making Skills for Rheumatologists.

Mahmood S, Hazes JMW, Veldt P, van Riel P, Landewé R, Moens HB, Pasma A.

J Rheumatol. 2019 Apr 1. pii: jrheum.180780. doi: 10.3899/jrheum.180780. [Epub ahead of print]

PMID:
30936289
5.

Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.

Lamers-Karnebeek FBG, Jacobs JWG, Radstake TRDJ, van Riel PLCM, Jansen TL.

Rheumatology (Oxford). 2019 Mar 1;58(3):427-431. doi: 10.1093/rheumatology/key292.

PMID:
30383251
6.

Tailored, Therapist-Guided Internet-Based Cognitive Behavioral Therapy Compared to Care as Usual for Patients With Rheumatoid Arthritis: Economic Evaluation of a Randomized Controlled Trial.

Ferwerda M, van Beugen S, van Middendorp H, Visser H, Vonkeman H, Creemers M, van Riel P, Kievit W, Evers A.

J Med Internet Res. 2018 Oct 11;20(10):e260. doi: 10.2196/jmir.9997.

7.

Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis.

Renskers L, van Uden RJJC, Huis AMP, Rongen SAA, Teerenstra S, van Riel PLCM.

Clin Rheumatol. 2018 Dec;37(12):3191-3199. doi: 10.1007/s10067-018-4285-x. Epub 2018 Sep 12.

PMID:
30209696
8.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

9.

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.

Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2018 Oct;70(10):1557-1564. doi: 10.1002/art.40546. Epub 2018 Aug 23.

PMID:
29745059
10.

Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis.

Bhansing KJ, VAN Rosmalen MH, VAN Engelen BG, VAN Riel PL, Pillen S, Vonk MC.

J Rheumatol. 2018 Mar;45(3):441-442. doi: 10.3899/jrheum.171188. No abstract available.

PMID:
29496919
11.

2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis.

Radner H, Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich KL, Zabalan C, van Eijk-Hustings Y, Williamson PR, Balanescu A, Burmester GR, Carmona L, Dougados M, Finckh A, Haugeberg G, Hetland ML, Oliver S, Porter D, Raza K, Ryan P, Santos MJ, van der Helm-van Mil A, van Riel P, von Krause G, Zavada J, Dixon WG, Askling J.

Ann Rheum Dis. 2018 Apr;77(4):476-479. doi: 10.1136/annrheumdis-2017-212256. Epub 2018 Jan 4.

PMID:
29301783
12.

Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care.

Weijers JM, Rongen-van Dartel SAA, Hoevenaars DMGMF, Rubens M, Hulscher MEJL, van Riel PLCM.

Ann Rheum Dis. 2018 Apr;77(4):480-483. doi: 10.1136/annrheumdis-2017-212392. Epub 2017 Nov 22. Review.

PMID:
29167154
13.

Tailored Therapist-guided Internet-based Cognitive-behavioural Treatment for Psoriasis and Rheumatoid Arthritis: Two Case Reports.

Koulil SS, Ferwerda M, van Beugen S, van Middendorp H, van de Kerkhof PCM, van Riel PLCM, Evers AWM.

Acta Derm Venereol. 2018 Feb 7;98(2):225-233. doi: 10.2340/00015555-2803.

14.

Evaluating quality of care in rheumatoid arthritis: the patient perspective.

Mahmood S, van Oosterhout M, de Jong S, Landewé R, van Riel P, van Tuyl LHD.

RMD Open. 2017 Jun 29;3(1):e000411. doi: 10.1136/rmdopen-2016-000411. eCollection 2017. No abstract available.

15.

Pulmonary arterial hypertension, a novelty in idiopathic inflammatory myopathies: insights and first experiences with vasoactive therapy.

Bhansing KJ, Vonk-Noordegraaf A, Oosterveer FP, van Riel PL, Vonk MC.

RMD Open. 2017 Jun 9;3(1):e000331. doi: 10.1136/rmdopen-2016-000331. eCollection 2017.

16.

Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel PLCM, Gabriel SE, Matteson EL, Kvien TK, Douglas K, Sandoo A, Arts E, Wållberg-Jonsson S, Innala L, Karpouzas G, Dessein PH, Tsang L, El-Gabalawy H, Hitchon C, Ramos VP, Yáñez IC, Sfikakis PP, Zampeli E, Gonzalez-Gay MA, Corrales A, Laar MV, Vonkeman HE, Meek I, Semb AG; A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA).

Ann Rheum Dis. 2018 Jan;77(1):48-54. doi: 10.1136/annrheumdis-2017-211735. Epub 2017 Sep 6.

17.

Muscle ultrasonography is a potential tool for detecting fasciitis in dermatomyositis and polymyositis: comment on the article by Yoshida et al.

Bhansing KJ, van Rosmalen MH, van Engelen BG, van Riel PL, Pillen S, Vonk MC.

Arthritis Rheumatol. 2017 Nov;69(11):2248-2249. doi: 10.1002/art.40240. No abstract available.

18.

Development of an item bank to measure factual disease and treatment related knowledge of rheumatoid arthritis patients in the treat to target era.

de Jonge MJ, Oude Voshaar MAH, Huis AMP, van de Laar MAFJ, Hulscher MEJL, van Riel PLCM.

Patient Educ Couns. 2018 Jan;101(1):67-73. doi: 10.1016/j.pec.2017.07.019. Epub 2017 Jul 21.

PMID:
28811047
19.

Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.

Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, Tchetverikov I, Vreugdenhil SA, van Woerkom JM, Goekoop-Ruiterman YPM, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):516-524. doi: 10.1002/acr.23315.

20.

Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study.

Arts EE, Fransen J, Den Broeder AA, van Riel PLCM, Popa CD.

Ann Rheum Dis. 2017 Oct;76(10):1693-1699. doi: 10.1136/annrheumdis-2016-210997. Epub 2017 Jun 12.

PMID:
28606965
21.

Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.

Lamers-Karnebeek FB, Luime JJ, Ten Cate DF, Teerenstra S, Swen NWAA, Gerards AH, Hendrikx J, van Rooyen EM, Voorneman R, Haagsma C, Basoski N, de Jager M, Ghiti Moghadam M, Efde MN, Goekoop-Ruiterman YPM, van Riel PLCM, Jacobs JWG, Jansen TL.

Rheumatology (Oxford). 2017 Sep 1;56(9):1560-1565. doi: 10.1093/rheumatology/kex184.

PMID:
28595367
22.

The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength.

Worm-Smeitink M, Gielissen M, Bloot L, van Laarhoven HWM, van Engelen BGM, van Riel P, Bleijenberg G, Nikolaus S, Knoop H.

J Psychosom Res. 2017 Jul;98:40-46. doi: 10.1016/j.jpsychores.2017.05.007. Epub 2017 May 8.

PMID:
28554371
23.

Correction: Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Kitas GD, van Riel PL, Gabriel SE, Semb AG; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA).

PLoS One. 2017 Apr 7;12(4):e0175605. doi: 10.1371/journal.pone.0175605. eCollection 2017.

24.

Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related).

Fautrel B, Balsa A, Van Riel P, Casillas M, Capron JP, Cueille C, de la Torre I.

Curr Med Res Opin. 2017 Jul;33(7):1231-1246. doi: 10.1080/03007995.2017.1313209. Epub 2017 Apr 28. Review.

PMID:
28358217
25.

Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries.

Crowson CS, Gabriel SE, Semb AG, van Riel PLCM, Karpouzas G, Dessein PH, Hitchon C, Pascual-Ramos V, Kitas GD; Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis.

Rheumatology (Oxford). 2017 Jul 1;56(7):1102-1110. doi: 10.1093/rheumatology/kex038.

26.

Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Kitas GD, van Riel PL, Gabriel SE, Semb AG; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA).

PLoS One. 2017 Mar 23;12(3):e0174656. doi: 10.1371/journal.pone.0174656. eCollection 2017. Erratum in: PLoS One. 2017 Apr 7;12 (4):e0175605.

27.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

28.

IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis.

Damen MS, Agca R, Holewijn S, de Graaf J, Dos Santos JC, van Riel PL, Fransen J, Coenen MJ, Nurmohamed MT, Netea MG, Dinarello CA, Joosten LA, Heinhuis B, Popa CD.

Sci Rep. 2017 Jan 30;7:41629. doi: 10.1038/srep41629.

29.

The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.

Nikiphorou E, Galloway J, van Riel P, Yazici Y, Haugeberg G, Ostor A, Gogus F, Kauppi M, Sokka T; QUEST-RA.

Clin Exp Rheumatol. 2017 May-Jun;35(3):477-483. Epub 2017 Jan 27.

PMID:
28134086
30.

A tailored-guided internet-based cognitive-behavioral intervention for patients with rheumatoid arthritis as an adjunct to standard rheumatological care: results of a randomized controlled trial.

Ferwerda M, van Beugen S, van Middendorp H, Spillekom-van Koulil S, Donders ART, Visser H, Taal E, Creemers MCW, van Riel PCLM, Evers AWM.

Pain. 2017 May;158(5):868-878. doi: 10.1097/j.pain.0000000000000845.

PMID:
28106666
31.

A different perspective: Inflammatory rheumatic diseases and other organs.

Kitas GD, van Riel PL.

Best Pract Res Clin Rheumatol. 2016 Oct;30(5):787-788. doi: 10.1016/j.berh.2016.10.014. Epub 2016 Nov 22. No abstract available.

PMID:
27964788
32.

Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools.

van Riel P, Alten R, Combe B, Abdulganieva D, Bousquet P, Courtenay M, Curiale C, Gómez-Centeno A, Haugeberg G, Leeb B, Puolakka K, Ravelli A, Rintelen B, Sarzi-Puttini P.

RMD Open. 2016 Nov 24;2(2):e000302. eCollection 2016. Review.

33.

A pilot study of CXCL8 levels in crystal proven gout patients during allopurinol treatment and their association with cardiovascular disease.

Kienhorst L, Janssens H, Radstake T, van Riel P, Jacobs J, van Koolwijk E, van Lochem E, Janssen M.

Joint Bone Spine. 2017 Dec;84(6):709-713. doi: 10.1016/j.jbspin.2016.10.013. Epub 2016 Nov 25.

PMID:
27894951
34.

The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis.

van Riel PL, Renskers L.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S40-S44. Epub 2016 Oct 18. Review.

35.

Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis.

Hendrikx J, de Jonge MJ, Fransen J, Kievit W, van Riel PL.

RMD Open. 2016 Aug 18;2(2):e000202. doi: 10.1136/rmdopen-2015-000202. eCollection 2016.

36.

Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It.

Bhansing KJ, van Riel PL, van Engelen BG, Fransen J, Vonk MC.

J Rheumatol. 2016 Oct;43(10):1838-1843. Epub 2016 Aug 15.

PMID:
27528573
37.

Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.

Manders SH, Kievit W, Jansen TL, Stolk JN, Visser H, Schilder AM, Vonkeman HE, Adang E, van de Laar MA, van Riel PL.

J Rheumatol. 2016 Oct;43(10):1787-1794. Epub 2016 Aug 1.

PMID:
27481900
38.

Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF.

Arthritis Res Ther. 2016 Jun 20;18(1):144. No abstract available.

39.

Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use.

Mavrogeni SI, Kitas GD, Dimitroulas T, Sfikakis PP, Seo P, Gabriel S, Patel AR, Gargani L, Bombardieri S, Matucci-Cerinic M, Lombardi M, Pepe A, Aletras AH, Kolovou G, Miszalski T, van Riel P, Semb A, Gonzalez-Gay MA, Dessein P, Karpouzas G, Puntmann V, Nagel E, Bratis K, Karabela G, Stavropoulos E, Katsifis G, Koutsogeorgopoulou L, van Rossum A, Rademakers F, Pohost G, Lima JA.

Int J Cardiol. 2016 Aug 15;217:135-48. doi: 10.1016/j.ijcard.2016.04.158. Epub 2016 Apr 27. Review.

PMID:
27179903
40.

Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis.

Kievit W, Maurits JS, Arts EE, van Riel PL, Fransen J, Popa CD.

Arthritis Care Res (Hoboken). 2017 Feb;69(2):175-182. doi: 10.1002/acr.22929.

41.

A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis.

Rongen-van Dartel SA, Repping-Wuts H, Donders R, van Hoogmoed D, Knoop H, Bleijenberg G, van Riel PL, Fransen J.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):200-6. Epub 2016 Mar 25.

PMID:
27049923
42.

The influence of patient perceptions of disease on medication intensification in daily practice.

Hendrikx J, Kievit W, Fransen J, van Riel PL.

Rheumatology (Oxford). 2016 Nov;55(11):1938-1945. Epub 2016 Mar 23.

PMID:
27009827
43.

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF; Rheumatic Diseases Portuguese Register.

Arthritis Res Ther. 2016 Feb 16;18:50. doi: 10.1186/s13075-016-0951-z. Erratum in: Arthritis Res Ther. 2016;18(1):144.

44.

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.

Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2016 Aug;68(8):1810-7. doi: 10.1002/art.39626.

45.

Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.

Steunebrink LM, Vonkeman HE, ten Klooster PM, Hoekstra M, van Riel PL, van de Laar MA.

Clin Rheumatol. 2016 Mar;35(3):609-15. doi: 10.1007/s10067-016-3191-3. Epub 2016 Feb 6.

46.

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.

van den Reek JM, Pijls PA, Tummers M, van Riel PC, Kievit W, Hoentjen F, de Jong EM.

J Am Acad Dermatol. 2016 Jan;74(1):177-9. doi: 10.1016/j.jaad.2015.08.010. No abstract available.

PMID:
26702800
47.

Quality in rheumatoid arthritis care.

Mahmood S, Lesuis N, van Tuyl LH, van Riel P, Landewé R.

Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):664-79. doi: 10.1016/j.berh.2015.09.009. Epub 2015 Nov 7. Review.

PMID:
26697773
48.

Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare.

Hendrikx J, Fransen J, van Riel PL.

RMD Open. 2015 Nov 19;1(1):e000114. doi: 10.1136/rmdopen-2015-000114. eCollection 2015.

49.

Measuring the Therapeutic Relationship in Internet-Based Interventions.

Ferwerda M, van Beugen S, van Riel PC, van de Kerkhof PC, de Jong EM, Smit JV, Zeeuwen-Franssen ME, Kroft EB, Visser H, Vonkeman HE, Creemers MC, van Middendorp H, Evers AW.

Psychother Psychosom. 2016;85(1):47-9. doi: 10.1159/000435958. Epub 2015 Nov 27. No abstract available.

PMID:
26610272
50.

Impaired Porphyromonas gingivalis-Induced Tumor Necrosis Factor Production by Dendritic Cells Typifies Patients With Rheumatoid Arthritis.

Santegoets KC, Wenink MH, Braga FA, Cossu M, Lamers-Karnebeek FB, van Riel PL, Sturm PD, van den Berg WB, Radstake TR.

Arthritis Rheumatol. 2016 Apr;68(4):795-804. doi: 10.1002/art.39514.

Supplemental Content

Loading ...
Support Center